InvestorsHub Logo
Followers 128
Posts 12944
Boards Moderated 0
Alias Born 04/02/2017

Re: drugmanrx post# 28064

Friday, 01/28/2022 3:35:01 PM

Friday, January 28, 2022 3:35:01 PM

Post# of 29771
Maybe you should ask Tony that question, we shareholders have a right (probably not on the OTC tho smile) to know how things are progressing with that proof of concept.

Our CEO sure made all the mistakes to be expected from a rookie OTC CEO. Well, if Ennis-Flint really approached PMPG, it means the potential is still there for another round of bargaining.

I'd rather have them not spend any money on a proof of concept if the stakeholders surrounding the CEO are of the impression that it's not duable with the resources and alliances at hand.

So even if the proof of concept is doomed, the high risk / reward potential still remains in the form of these extremely strategic patents moving forward.

But these patents are in fact property of NPI...

http://www.npimobile.com/wp-content/uploads/2017/02/NPI_Infographic_Web_2017-683x1024.jpg

By the way, did you read: "additional patents pending"? Didn't catch my eye before.

On every highway, on every corner...

Maybe the whole project is too ambitious for an OTC company to develop, maybe they're just waiting for the right timing to sell off the whole idea and the patents to the highest bidder, maybe they're just sitting on these patents and they already know the proof of concept has been disproved, maybe they're going to restructure the whole holding company in face of a buyout? Like a Prototype car that never was designed to hit the road and be commercialized in the first place.

I think these questions raise interesting issues at hand. Think about some of these biotech company's that have been sitting on certain patents for years on, like ENZC or RDGL, when the timing was right (COVID-19 for example, cfr mRNA tech) the stock went BOOM.